What antihypertensive regimen is recommended for a patient with hypertension after a myocardial infarction, including beta‑blocker, ACE inhibitor or ARB, thiazide diuretic, mineralocorticoid receptor antagonist, and calcium‑channel blocker, with considerations for reduced left‑ventricular ejection fraction and renal function?

Blood Pressure Medications for Hypertension Post-MI

All post-MI patients with hypertension should be started on a beta-blocker and an ACE inhibitor (or ARB if ACE inhibitor intolerant) within the first 24 hours, with aldosterone antagonist added for those with LVEF ≤40% plus heart failure or diabetes, and thiazide diuretics or calcium channel blockers added as needed for blood pressure control. 1

Core Medication Regimen (Start Immediately)

Beta-Blockers (Class I Recommendation)

• Start within 24 hours and continue indefinitely in all post-MI patients unless contraindicated 1
• Proven mortality reduction of 23% in long-term trials 1
• Use carvedilol, metoprolol succinate, or bisoprolol specifically, as these have demonstrated mortality reduction 1
• Contraindications include systolic BP <90 mmHg, severe bradycardia (<50 bpm), signs of heart failure at presentation, or risk of cardiogenic shock 1, 2

ACE Inhibitors (Class I Recommendation)

• Start within 24 hours in all patients with LVEF <40%, hypertension, diabetes, chronic kidney disease, or anterior MI 1
• Continue indefinitely—mortality reduction of 20-25% in high-risk patients with LV dysfunction 1
• Even in lower-risk patients with normal LVEF, ACE inhibitors are reasonable (Class IIa) 1
• Greatest benefit in patients with heart failure at presentation (23 lives saved per 1000 patients) and anterior MI (11 lives saved per 1000) 1

Angiotensin Receptor Blockers (Alternative to ACE Inhibitors)

• Use ARBs only if ACE inhibitor intolerant or contraindicated 1
• Valsartan and candesartan have established efficacy post-MI 1
• ARBs are as effective as ACE inhibitors but have less robust evidence base 1
• Do NOT combine ARB with ACE inhibitor—this increases adverse events without improving survival 1

Additional Medications Based on Specific Criteria

Aldosterone Antagonists (Class I for High-Risk Patients)

• Add eplerenone or spironolactone if patient meets ALL of the following criteria: 1
  • Already receiving therapeutic doses of ACE inhibitor AND beta-blocker
  • LVEF ≤40%
  • Either symptomatic heart failure OR diabetes mellitus
  • Serum creatinine ≤2.5 mg/dL (men) or ≤2.0 mg/dL (women)
  • Serum potassium ≤5.0 mEq/L
• Provides 15% reduction in total mortality and 21% reduction in sudden cardiac death 1
• Critical monitoring required: Close follow-up of potassium and creatinine, especially with estimated creatinine clearance <50 mL/min 1
• Avoid if estimated GFR <45 mL/min 1

Thiazide Diuretics (For Additional BP Control)

• Add thiazide or thiazide-type diuretic if BP remains elevated despite beta-blocker and ACE inhibitor/ARB 1, 3
• Use loop diuretics instead if patient has heart failure (NYHA class III or IV) or CKD with estimated GFR <45 mL/min 1
• Monitor potassium carefully to avoid hypokalemia, which may precipitate arrhythmias post-MI 1

Calcium Channel Blockers (For Refractory Hypertension)

• Add dihydropyridine CCB (amlodipine, nifedipine) if additional BP lowering needed beyond beta-blocker, ACE inhibitor/ARB, and thiazide 1, 4
• Do NOT use verapamil or diltiazem in combination with beta-blockers 4
• Non-dihydropyridine CCBs (verapamil, diltiazem) can substitute for beta-blockers only if beta-blockers are contraindicated or not tolerated 4

Blood Pressure Targets Post-MI

• Target BP <130/80 mmHg for patients with known CAD 4
• Target BP <120/80 mmHg for patients with left ventricular dysfunction 4
• Standard target of <140/90 mmHg is insufficient for post-MI patients 4

Algorithmic Approach to Medication Selection

Step 1 (Within 24 hours):

• Beta-blocker + ACE inhibitor (or ARB if intolerant) 1, 2

Step 2 (Days 3-14 post-MI):

• Assess LVEF, presence of heart failure, diabetes status 1
• If LVEF ≤40% AND (heart failure OR diabetes) AND adequate renal function → Add aldosterone antagonist 1

Step 3 (If BP not at target):

• Add thiazide diuretic (or loop diuretic if heart failure/advanced CKD) 1, 3

Step 4 (If BP still not at target):

• Add dihydropyridine calcium channel blocker 1, 4

Critical Pitfalls to Avoid

• Never combine ACE inhibitor with ARB—this increases adverse events including hypotension and renal dysfunction without mortality benefit 1
• Never use NSAIDs in post-MI patients—these should be discontinued during hospitalization due to increased risk of major adverse cardiac events, impaired infarct healing, and possible increased rupture risk 1, 2
• Do not withhold aldosterone antagonists due to excessive caution about hyperkalemia—these are underused despite proven mortality benefit; appropriate monitoring mitigates risk 1
• Do not use non-dihydropyridine CCBs (verapamil, diltiazem) with beta-blockers—risk of excessive bradycardia and heart block 4
• Do not delay ACE inhibitor initiation in high-risk patients (anterior MI, heart failure, LVEF ≤40%)—greatest benefit occurs when started within 24 hours 1

Special Considerations for Reduced LVEF

Patients with LVEF ≤40% require the most aggressive regimen:

• Beta-blocker (mortality reduction 23%) 1
• ACE inhibitor (mortality reduction 20-25%) 1
• Aldosterone antagonist if also have heart failure or diabetes (mortality reduction 15%) 1
• Diuretic for volume management 1
• This combination provides incremental benefit, with aldosterone antagonists effective even when 87% of patients are on ACE inhibitors and 75% on beta-blockers 1

Renal Function Considerations

• Creatinine >2.5 mg/dL (men) or >2.0 mg/dL (women): Avoid aldosterone antagonists 1
• Estimated GFR <45 mL/min: Use loop diuretics instead of thiazides; avoid aldosterone antagonists 1
• Monitor renal function closely when initiating ACE inhibitors/ARBs, especially in combination with aldosterone antagonists 1